The maker of weight-loss drug Wegovy has become Europe's most valuable firm, dethroning the French luxury conglomerate LVMH. Shares rose after the Danish pharmaceutical giant, Novo Nordisk, launched the popular drug in the UK. At the close of trading on Monday, the firm had a stock market valuation of $428bn (£339bn). The drug is now available on the National Health Service in the UK and also on the private market. Wegovy is an obesity treatment that is taken once a week which tricks people into thinking that they are already full, so they end up eating less and losing weight. Famous personalities such as Elon Musk are among the reported users of the drug, which has captivated Hollywood and the public more widely since it was approved by regulators in the US in 2021. Wegovy and Ozempic - a diabetes treatment with similar effects - have been described as "miracle" drugs. But experts warn the jabs are not a quick fix nor a substitute for a healthy diet and exercise. In trials, users often put weight back on after stopping treatment.
